爱特医疗 ATRC

Michael H. Carrel. Mr. Carrel has been President, Chief Executive Officer and director since November 2012. Since joining AtriCure, Mr. Carrel has fostered a patient-first company mission by focusing on the three core areas: innovation, clinical science and education. This strategy led AtriCure to invest in the development of a robust pipeline of novel products and groundbreaking clinical trials for the treatment of atrial fibrillation (Afib), left atrial appendage management and pain management, and continue to expand its market presence globally. These investments have driven significant growth in AtriCure's revenue, from $82 million in 2013 to $535 million in 2025, and allowed us to help more than one million patients to date. Further, market cap has increased from $115 million to approximately $2 billion as of December 31, 2025 under his leadership. During Mr. Carrel's tenure, AtriCure has acquired several companies, adding leading ablation and appendage management technologies to further AtriCure's market position worldwide. His career includes successful leadership in global organizations in healthcare and technology industries. Prior to joining AtriCure, Mr. Carrel was President and Chief Executive Officer of Vital Images, Inc., a publicly-traded medical imaging software company that was acquired by Toshiba Medical Systems Corporation. Previously, Mr. Carrel served as President and CEO of Zamba Corporation, a publicly-traded technology company, and as Chief Financial Officer of NextNet Wireless, Inc., both of which achieved successful acquisition exits. Mr. Carrel currently serves as the Board Chair of Big Brothers Big Sisters of America and has been a director since 2021. He has served on the Board of Medical Device Manufacturers Association (MDMA) since 2015 and serves on the Board of AdvaMed . He previously served as Board Chair of Axonics, Inc. from 2019 to 2024, prior to its acquisition by Boston Scientific in 2024. Mr. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Wharton School at the University of Pennsylvania.

Douglas J. Seith has served as our Chief Operating Officer since January 2015, having previously served as our Senior Vice President, Sales and Marketing from 2013 to 2014 and as our Vice President, United States Sales from 2011 to 2013. Since joining AtriCure in 2004 as a Regional Sales Leader, Mr. Seith has held a variety of progressive sales and sales leadership positions, including Area Director roles. Mr. Seith has over 30 years of cardiothoracic, cardiology and general surgery sales and sales and marketing leadership experience. Prior to joining AtriCure, Mr. Seith held sales leadership and sales positions with A-Med/EmoblX, Inc., where he was the Vice President of Sales, Heartport, Inc., Scimed Life Systems, a division of Boston Scientific, Inc. and Automated Instruments (a division of Unites States Surgical Corporation). Mr. Seith received his B.A. from Ohio Wesleyan University.

Angela L. Wirick was appointed Chief Financial Officer in August 2020, and leads the Company's Finance, Information Technology and Human Resources functions. Immediately prior to this, Ms. Wirick served as our Vice President, Finance for four years, where she led the global accounting and finance functions of the Company and supported strategic initiatives such as acquisitions and capital raises. Ms. Wirick joined the Company in 2014 as Director, Finance. Ms. Wirick began her career in public accounting at Arthur Andersen LLP and Deloitte & Touche LLP, serving clients in a variety of industries over fourteen years. Ms. Wirick currently serves on the Business Advisory Council for the School of Business Administration at the University of Dayton. Ms. Wirick received her B.S.B.A. in Accounting from the University of Dayton and is a Certified Public Accountant (Inactive).

Salvatore Privitera, J.D. has served as our Chief Technical Officer since January 2017. Prior to joining AtriCure, Mr. Privitera served as Vice President of Research and Development at Bard Medical (BMD), a division of C.R. Bard, Inc. Prior to his role at BMD, Mr. Privitera worked for AtriCure as the Vice President of Engineering and Product Development for nine years. Prior to AtriCure, Mr. Privitera worked at Ethicon Endo-Surgery, a Johnson and Johnson company, in a variety of research, development and operations roles. Mr. Privitera is a named inventor on over fifty U.S. patents. He is a member of the Advisory Board for the University of Buffalo School of Biomedical Engineering and serves on the Board of Directors of the Cincinnati Chapter of the American Heart Association as well as the Ohio Life Sciences. Mr. Privitera received his B.S. from the University of Buffalo, his M.B.A. from Xavier University and his J.D. from Northern Kentucky University.

Justin J. Noznesky has served as our Chief Marketing and Strategy Officer since March 2021, having previously served as our Senior Vice President, Marketing and Business Development since March 2016, as our Vice President, Marketing and Business Development since January 2014. Mr. Noznesky has over 20 years of experience in roles that include leading strategic planning, mergers and acquisitions, global strategic marketing and communications, and healthcare economics and reimbursement. From 2004 to 2013, Mr. Noznesky various leadership positions at Vital Images, Inc., a subsidiary of Toshiba Medical Systems Corporation, including Vice President, Marketing and Business Development. Prior to working for Vital Images, Mr. Noznesky worked at UnitedHealth Group in Corporate Finance and at Arthur Andersen LLP as a senior auditor. Mr. Noznesky received his B.A. from Bethel University.

Robert S. White. Mr. White has served as a director since March 2013. Mr. White is an Operating Partner of EW Healthcare Partners. Previously, he served as President and Chief Executive Officer of Entellus Medical, Inc., which was acquired by Stryker Corporation and as President and CEO of TYRX, which was acquired by Medtronic, Inc. Mr. White held several senior leadership positions with Medtronic, Inc., including President of Medtronic Kyphon, President of Physio Control and Vice President of U.S. Sales and Global Marketing for Cardiac Rhythm Disease Management. He currently serves on the boards of several privately-held medical device companies including BioTissue Holdings Inc., Vital Connect, Cardiac Dimensions, and Melodi Health. Mr. White holds a B.S. in Aerospace Engineering from the University of Missouri-Rolla and an M.B.A. from Cornell University.

Regina E. Groves. Ms. Groves has served as one of our directors since March 2017. Most recently, Ms. Groves held multiple leadership roles at Stimwave, LLC, including serving as Chief Financial Officer and Chief Operating Officer, and served as a director of Stimwave Technologies, Inc. Previously, Ms. Groves served as the Chief Executive Officer of REVA Medical, Inc., a formerly publicly-traded medical device company focused on the bioresorbable polymer technologies for vascular applications. Prior to REVA Medical, she held various leadership positions at Medtronic, Inc. from 2002 to 2015, including Vice President and General Manager of AF Solutions, Cardiac Rhythm and Heart Failure division, where she successfully developed and executed strategies to re-enter the catheter-based Afib ablation market and achieved the goal to be market leader in paroxysmal, or intermittent, Afib ablation. Her experience at Medtronic included senior roles as Vice President of Quality and Regulatory for Medtronic's Cardiac Rhythm Disease Management (CRDM) and Vice President and General Manager for Patient Management CRDM. Ms. Groves currently serves on the Board of Directors of Fulgent Genetics, Inc., a publicly traded company providing technology-based therapeutic development and clinical diagnostics and several privately-held life science companies. Ms. Groves holds a B.S. in Pharmacy from the University of Florida and an M.B.A. from Harvard Graduate School of Business Administration. Ms. Groves qualifies as an audit committee financial expert under SEC rules, holds a CERT Certificate in Cybersecurity Oversight and completed A Director's Guide to AI: Strategy, Governance & Value Creation from the National Association of Corporate Directors (NACD).

Sven A. Wehrwein. Mr. Wehrwein has served as one of our directors since November 2016. Mr. Wehrwein has been an independent financial consultant to emerging companies since 1999 and has more than three decades of experience in accounting, finance, investment banking and executive leadership. Mr. Wehrwein has experience as a certified public accountant (inactive), investment banker to emerging-growth companies, chief financial officer and audit committee and board chair. Mr. Wehrwein currently serves on the boards of two publicly-traded companies: Proto Labs, Inc., a custom prototype manufacturer and SPS Commerce, Inc., a supply-chain management software company, and has previously served on the boards of several medical device and high-growth companies. Mr. Wehrwein holds a B.S. in Business from Loyola University of Chicago and an M.S. in Management from the Sloan School, MIT. Mr. Wehrwein qualifies as an audit committee financial expert under SEC rules. As Chair of the Audit Committee, Mr. Wehrwein also keeps the Board informed of current audit issues and collaborates with our independent auditors and senior management team.

Shlomo Nachman. Mr. Nachman has served as a member of the Board of Directors since January 2024. Mr. Nachman held multiple senior operating roles at Johnson & Johnson, most recently serving as Company Group Chairman of Cardiovascular and Specialty Solutions and Vision Groups within the Medical Devices business from 2013 through 2023. In this role, he led a diverse portfolio of six medical device businesses and served on the Medical Devices Group Operating Committee. Mr. Nachman previously served as Worldwide President of Biosense Webster and Cordis. He currently serves on the boards of several private medical device companies and the Arnold and Mable Beckman Foundation, a foundation focused on supporting research in chemistry and life sciences. Mr. Nachman holds a Bachelor's Degree in Management and Economics from Technion - Israel Institute of Technology. Mr. Nachman has over 25 years of experience in the medical device industry and deep knowledge of many related business aspects including research and development, operations, and reinventing commercial models. This experience in operational roles, including strategic planning, market development and risk management, are beneficial to the management team and the Board.

Maggie Yuen. Ms. Yuen has served as one of our directors since June 2021. Ms. Yuen has served as Chief Financial Officer of Penumbra, Inc., a global healthcare company focused on innovative therapies, since December 2019. Penumbra recently announced it has entered into a definitive agreement to be acquired by Boston Scientific. Ms. Yuen is a seasoned executive with more than 25 years of experience within the manufacturing, medical devices and life science industries. Over the course of her career, she has developed financial and operational expertise at both multibillion-dollar public companies and entrepreneurial start-up ventures. Previously, Ms. Yuen served as Vice President of Finance and Divisional Chief Financial Officer for the Genetic Science Division for Thermo Fisher Scientific Inc. and Chief Financial Officer at Mirion Technologies. She has also held leadership roles at Boston Scientific, GLU Mobile, Lifescan Inc., Picker International, Rockwell Automation and Eaton Corporation. Ms. Yuen holds a B.A.Sc. in Accounting, a Master of Accountancy and an M.B.A. from Case Western Reserve University. She qualifies as an audit committee financial expert under SEC rules.

Karl S. Dahlquist, J.D., C.C.E.P. has served as our Chief Legal Officer since March 2019. Mr. Dahlquist joined the Company in August 2013 as Vice President, Legal and Regulatory Affairs and Chief Compliance Officer. Mr. Dahlquist began his career as a lawyer specializing in medical device litigation and regulation at an international law firm. In 1999, he left private practice to join the legal department of Medtronic, Inc., where he was Senior Counsel to the Spinal & Biologics business. Mr. Dahlquist subsequently served in a variety of senior legal, compliance and quality management roles with St. Jude Medical, GE Healthcare and Johnson & Johnson. He attended the University of Michigan in Ann Arbor, where he earned Bachelor of Science and Juris Doctor degrees.